Vitreomacular Interface Clinical Trial
Official title:
Influence of Intravitreal Anti-vascular Endothelial Growth Factor Administration on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration
Purpose:
To assess the influence of intravitreal anti-vascular endothelial growth factor (anti-VEGF)
administration on vitreomacular interface- and retinal morphology in eyes with neovascular
age-related macular degeneration (AMD) and to identify morphological markers potentially
influencing disease prognosis.
Methods:
43 patients (51 eyes) with treatment naïve neovascular AMD subsequently treated with
Bevacizumab 1.25mg (in 0.05ml of solution) were monitored until month 12 of follow-up.
Following a loading dose of 3 monthly intravitreal anti-VEGF injections, patients were
treated as-needed [pro re nata (PRN)]. Functional and morphological changes were assessed
using Spectral Domain Optical Coherence Tomography (SD-OCT).
This retrospective study included 43 treatment-naive patients (51 eyes) with neovascular AMD over the course of 12 months. Patients were treated with a loading dose of 3 initial monthly anti-VEGF injections (Bevacizumab 1.25mg in 0.05ml of solution-Avastin®) and were followed monthly until year 1. Re-treatment was performed if needed (pro re nata-PRN) as previously reported. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02933905 -
Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection
|
N/A |